## IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

MDL 2724 16-MD-2724

THIS DOCUMENT RELATES TO:

HON. CYNTHIA M. RUFE

1199SEIU National Benefit Fund v. Actavis Holdco U.S., Inc.

Civil Action No. 19-6011

**ORDER** 

AND NOW, this APPROVED.

It is so **ORDERED**.

BY THE COURT:

CYNTHIA M. RUFE, J.

# IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

1199SEIU NATIONAL BENEFIT FUND, et al.,

Plaintiffs,

v.

ACTAVIS HOLDCO U.S., INC., et al.,

Defendants.

MDL 2724 16-MD-2724 HON. CYNTHIA M. RUFE

CIVIL ACTION NO. 19-6011-CMR

JURY TRIAL DEMANDED

# JOINT STIPULATION TO WAIVE SERVICE AND EXTEND THE DEADLINE FOR DEFENDANTS TO RESPOND TO END-PAYER CLASS ACTION COMPLAINT

WHEREAS, 1199SEIU National Benefit Fund; 1199SEIU Greater New York Benefit Fund; 1199SEIU National Benefit Fund For Home Care Workers; 1199SEIU Licensed Practical Nurses Welfare Fund; American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan; Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc.; Self-Insured Schools of California; and Sergeants Benevolent Association Health and Welfare Fund, on behalf of themselves and all others similarly situated, (collectively "Plaintiffs") filed a Complaint on December 19, 2019 in 1199SEIU National Benefit Fund, et al. v. Actavis Holdco U.S., Inc., et al., Case No. 2:19-cv-06011-CMR, MDL No. 2724;

WHEREAS, Actavis Holdco U.S., Inc.; Actavis Elizabeth LLC; Actavis Pharma, Inc.;

Akorn Inc.; Akorn Sales, Inc.; Amneal Pharmaceuticals, Inc.; Amneal Pharmaceuticals, LLC; Apotex Corp.; Ascend Laboratories, LLC; Aurobindo Pharma USA, Inc.; Barr Pharmaceuticals, LLC; Bausch Health Americas, Inc.; Bausch Health US, LLC; Breckenridge Pharmaceutical, Inc.; Citron Pharma LLC; Dava Pharmaceuticals, LLC; Dr. Reddy's Laboratories, Inc.; Epic Pharma, LLC; Fougera Pharmaceuticals Inc.; Generics Bidco I, LLC; Glenmark Pharmaceuticals, Inc., USA; Greenstone, LLC; G&W Laboratories, Inc.; Heritage Pharmaceuticals, Inc.; Hikma Labs, Inc.; Hikma Pharmaceuticals USA, Inc.; Hi-Tech Pharmacal Co., Inc.; Impax Laboratories, LLC; Lannett Company, Inc.; Lupin Pharmaceuticals, Inc.; Mayne Pharma Inc.; Morton Grove Pharmaceuticals, Inc.; Mutual Pharmaceutical Company, Inc.; Mylan Inc.; Mylan Pharmaceuticals, Inc.; Oceanside Pharmaceuticals, Inc.; Par Pharmaceutical, Inc.; Perrigo New York, Inc.; Pfizer, Inc.; Pliva, Inc.; Sandoz Inc.; Sun Pharmaceutical Industries, Inc.; Taro Pharmaceuticals USA, Inc.; Teligent Inc.; Teva Pharmaceuticals USA, Inc.; Upsher-Smith Laboratories, LLC; VersaPharm, Inc.; West-Ward Columbus, Inc.; West-Ward Pharmaceuticals Inc.; Wockhardt USA LLC; and, Zydus Pharmaceuticals (USA) Inc. (collectively, "Waiving Defendants"), have agreed to waive service of the End-Payer Class Action Complaint, and the parties have reached an agreement to extend the time within which the Stipulating Defendants must move against, answer or otherwise respond to the End-Payer Class Action Complaint;

WHEREAS, on February 7, 2020, the End-Payer Class Action Complaint filed by Plaintiffs on December 19, 2019, was served on Defendant Camber Pharmaceuticals, Inc. ("Camber"), and Plaintiffs have agreed to extend the time within which Camber must move against, answer, or otherwise respond to the Complaint;

WHEREAS, on February 4, 2020, the End-Payer Class Action Complaint filed by

Plaintiffs on December 19, 2019 was served on Defendant Alvogen, Inc. ("Alvogen," and, together with Camber and the Waiving Defendants, the "Stipulating Defendants"), and Plaintiffs have agreed to extend the time within which Alvogen must move against, answer, or otherwise respond to the Complaint:

NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED by and among the undersigned counsel, on behalf of their respective clients, as follows:

- 1. The Waiving Defendants waive service of the End-Payer Class Action Complaint and Summonses pursuant to Federal Rule of Civil Procedure 4(d), and this Stipulation shall be deemed proof of that waiver pursuant to Federal Rule of Civil Procedure 4(d)(4).
- 2. The deadline for the Stipulating Defendants to move against, answer, or otherwise respond to the End-Payer Class Action Complaint is ADJOURNED until such time as the Court orders the filing of responses to complaints filed on or after May 10, 2019.
- 3. This Stipulation does not constitute a waiver by the Stipulating Defendants of any defense, including but not limited to those defenses provided under Federal Rule of Civil Procedure 12, except that the Stipulating Defendants do not contest personal jurisdiction.

IT IS SO STIPULATED.

Dated: February 14, 2020

/s/ Roberta D. Liebenberg
Roberta D. Liebenberg
FINE, KAPLAN AND BLACK, R.P.C.
One South Broad Street, 23<sup>rd</sup> Floor
Philadelphia, PA 19107
215-567-6565
rliebenberg@finekaplan.com

Liaison and Lead Counsel for End-Payer Plaintiffs

/s/ Jan P. Levine
Jan P. Levine
PEPPER HAMILTON LLP
3000 Two Logan Square
Eighteenth & Arch Streets

Philadelphia, PA 19103-2799 Tel: (215) 981-4000

Fax: (215) 981-4750 levinej@pepperlaw.com

/s/ Sheron Korpus

Sheron Korpus

KASOWITZ BENSON TORRES

LLP

1633 Broadway

New York, New York 10019

Tel: (212) 506-1700 Fax: (212) 506-1800 skorpus@kasowitz.com

/s/ Saul P. Morgenstern

Saul P. Morgenstern

ARNOLD & PORTER KAYE

SCHOLER LLP

250 W. 55th Street

New York, NY 10019

Tel: (212) 836-8000

Fax: (212) 836-8689

saul.morgenstern@arnoldporter.com

### /s/ Laura S. Shores

Laura S. Shores

ARNOLD & PORTER KAYE

SCHOLER LLP

601 Massachusetts Avenue

Washington, DC 20001

Tel: (202) 942-5000

Fax: (202) 942-5999

laura.shores@arnoldporter.com

#### /s/ Chul Pak

Chul Pak

WILSON SONSINI GOODRICH &

ROSATI

**Professional Corporation** 

1301 Avenue of the Americas, 40th Fl.

New York, NY 10019

Tel: (212) 999-5800

Fax: (212) 999-5899

cpak@wsgr.com

#### Liaison Counsel for Defendants